Li Jiaxing, Wang Xiao, Ding Jiayu, Zhu Yasheng, Min Wenjian, Kuang Wenbing, Yuan Kai, Sun Chengliang, Yang Peng
State Key Laboratory of Natural Medicines and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Acta Pharm Sin B. 2022 Jun;12(6):2808-2831. doi: 10.1016/j.apsb.2021.12.006. Epub 2021 Dec 17.
Hematopoietic stem cell (HSC) transplantation is the only curative therapy for many diseases. HSCs from umbilical cord blood (UCB) source have many advantages over from bone marrow. However, limited HSC dose in a single CB unit restrict its widespread use. Over the past two decades, HSC expansion with small molecules has been an effective approach for obtaining adequate HSCs. Till now, several small-molecule compounds have entered the phase I/II trials, showing safe and favorable pharmacological profiles. As HSC expansion has become a hot topic over recent years, many newly identified small molecules along with novel biological mechanisms for HSC expansion would help solve this challenging issue. Here, we will give an overview of HSC biology, discovery and medicinal chemistry development of small molecules, natural products targeting for HSC expansion, and their recent clinical progresses, as well as potential protein targets for HSC expansion.
造血干细胞(HSC)移植是许多疾病的唯一治愈性疗法。来自脐带血(UCB)来源的造血干细胞比来自骨髓的造血干细胞具有许多优势。然而,单个脐血单位中有限的造血干细胞剂量限制了其广泛应用。在过去二十年中,利用小分子进行造血干细胞扩增一直是获得足够造血干细胞的有效方法。到目前为止,几种小分子化合物已进入I/II期试验,显示出安全且良好的药理学特征。由于造血干细胞扩增近年来已成为一个热门话题,许多新发现的小分子以及造血干细胞扩增的新生物学机制将有助于解决这一具有挑战性的问题。在这里,我们将概述造血干细胞生物学、小分子的发现与药物化学发展、靶向造血干细胞扩增的天然产物及其近期临床进展,以及造血干细胞扩增的潜在蛋白质靶点。